Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 11/20 | 0.53 |
| ▸ | JAK3 | P52333 | 8/20 | 0.53 |
| ▸ | JAK2 | O60674 | 7/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062080 | 0.80 | JAK1 (0.74) | JAK1JAK3JAK2PRKCITYK2 | |
| Hydrochloric Acid SCHEMBL353625 | 0.79 | JAK1 (0.73) | JAK1JAK3JAK2PRKCITYK2 | |
| SCHEMBL15390126 | 0.72 | JAK1 (0.56) | JAK1JAK3JAK2ROCK2ROCK1 | |
| SCHEMBL352184 | 0.71 | JAK3 (0.58) | JAK1JAK3JAK2PRKCIROCK2 | |
| SCHEMBL10062093 | 0.71 | JAK3 (0.58) | JAK1JAK3JAK2PRKCIROCK2 | |
| SCHEMBL18559351 | 0.70 | JAK1 (0.48) | JAK1JAK3JAK2PBKTYK2 | |
| SCHEMBL10062197 | 0.70 | JAK1 (0.48) | JAK1JAK3JAK2PBKTYK2 | |
| SCHEMBL27891592 | 0.70 | JAK1 (0.86) | JAK1JAK3JAK2PRKCITYK2 | |
| SCHEMBL2104761 | 0.70 | JAK3 (1.00) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL4063065 | 0.70 | JAK2 (0.56) | JAK1JAK3JAK2PRKCIROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK1 2/4885JAK3 1/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.